Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication January 23, 2007
- Accepted for publication April 25, 2007
- Published online June 27, 2007.
Article Versions
- Earlier version (June 20, 2007 - 18:08).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2007 American Society of Nephrology
Author Information
- David R.W. Jayne*,
- Gill Gaskin†,
- Niels Rasmussen‡,
- Daniel Abramowicz§,
- Franco Ferrario‖,
- Loic Guillevin¶,
- Eduardo Mirapeix**,
- Caroline O.S. Savage††,
- Renato A. Sinico‖,
- Coen A. Stegeman‡‡,
- Kerstin W. Westman§§,
- Fokko J. van der Woude‖‖,
- Robert A.F. de Lind van Wijngaarden¶¶,
- Charles D. Pusey† and
- on behalf of the European Vasculitis Study Group
- *Department of Medicine, Addenbrooke's, Hospital, Cambridge, United Kingdom; †Renal Section, Division of Medicine, Imperial College, London, United Kingdom; ‡Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark; §Department of Immunology, Free University of Brussels, Brussels, Belgium; ‖Renal Immunopathology Centre, Ospedale San Carlo Borromeo, Milan, Italy; ¶Hôpital Cochin, Paris, France; **Hospital Clinic i Provincial, Barcelona, Spain; ††Department of Nephrology, University of Birmingham, Birmingham, United Kingdom; ‡‡Department of Nephrology, University Medical Center Groningen and University of Groningen, Groningen, Netherlands; §§Department of Nephrology and Transplantation, University Hospital of Malmö, Malmö, Sweden; ‖‖Department of Nephrology, University of Mannheim, Mannheim, Germany; and ¶¶Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands
- Correspondence:
Dr. David Jayne, Box 118, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. Phone: +44-1223-217259; Fax: +44-1223-586506; dj106{at}cam.ac.uk
Statistics from Altmetric.com
Article usage
Cited By...
In this issue
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
Jump to section
More in this TOC Section
Cited By...
- An update on the general management approach to common vasculitides
- Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease
- PEXIVAS: The End of Plasmapheresis for ANCA-Associated Vasculitis?
- Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study
- Management of ANCA associated vasculitis
- Rapidly progressive course of pauci-immune pulmonary capillaritis in a 70-year-old Asian male refractory to immunosuppression and plasma exchange
- Pulmonary-renal syndrome: diagnostic challenge
- Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
- Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
- ANCA Glomerulonephritis and Vasculitis
- Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
- Risk Factors for Renal Survival in Chinese Patients with Myeloperoxidase-ANCA-Associated GN
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
- Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in an elderly woman
- Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population
- CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides
- Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis
- Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis
- Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
- American Society of Nephrology Quiz and Questionnaire 2014: Glomerular Diseases
- Understanding the Role of Rituximab in ANCA GN: Regressing toward the Mean
- Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
- Pulmonary Thromboembolism and Diffuse Alveolar Hemorrhage in Granulomatosis With Polyangiitis Vasculitis
- The New Histopathologic Classification of ANCA-Associated GN and Its Association with Renal Outcomes in Childhood
- Predictors of Treatment Outcomes in ANCA-Associated Vasculitis with Severe Kidney Failure
- Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan
- Principles of Separation: Indications and Therapeutic Targets for Plasma Exchange
- Prediction of Outcomes in Crescentic IgA Nephropathy in a Multicenter Cohort Study
- Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)
- Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
- Pulmonary-renal syndrome: a life threatening but treatable condition
- Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis
- Renal disease in small-vessel vasculitis
- The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis
- Can We Identify Patients with Microscopic Polyangiitis Who Are at Risk of Relapse?
- A sore red eye with systemic involvement
- Diagnosis and management of ANCA associated vasculitis
- Elevated Soluble Flt1 Inhibits Endothelial Repair in PR3-ANCA-Associated Vasculitis
- Anti-Neutrophil Cytoplasmic Antibodies Stimulate Release of Neutrophil Microparticles
- Problems in pregnancy
- The 2010 Nephrology Quiz and Questionnaire: Part 2
- Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials
- The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
- Long-term patient survival in ANCA-associated vasculitis
- Myeloperoxidase-Specific Plasma Cell Depletion by Bortezomib Protects from Anti-Neutrophil Cytoplasmic Autoantibodies-Induced Glomerulonephritis
- Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
- Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial
- Histopathologic Classification of ANCA-Associated Glomerulonephritis
- Rituximab Treatment for Vasculitis
- Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis
- ANCA Disease: Where Is This Field Heading?
- Novel B Cell Therapeutic Targets in Transplantation and Immune-Mediated Glomerular Diseases
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
- Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
- EULAR recommendations for the management of primary small and medium vessel vasculitis
- Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
- A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure
- Removing Antibody and Preserving Glomeruli in ANCA Small-Vessel Vasculitis